Skyepharma PLC Says Abbott Laboratories Quits Flutiform Partnership

Published: Aug 20, 2010

LONDON, Aug 19 (Reuters) - Britain's SkyePharma (SKP.L) said Abbott Laboratories (ABT.N) has ended its deal to market SkyePharma's asthma drug Flutiform in the United States, after regulators imposed what could be insurmountable hurdles to approval.

Back to news